Beata Śpiewankiewicz

The Evaluation of Risk Factors Associated With Relapse and Recurrence of Borderline Ovarian Tumors With Long-Term Follow-up.

Objective The goal was to analyze the risk factors of relapse and to compare the type of recurrence in patients with borderline tumors treated and followed up in Oncologic Center in Warsaw. Materials and Methods This is a retrospective–prospective cohort study of 307 patients with confirmed borderline ovarian tumors treated in the Maria Sklodowska-Curie Memorial Cancer Center in Warsaw between 1994 and 2010. Univariate and multivariate analysis as well as Kaplan–Meier estimates were used to explore the impact of different covariates on progression-free survival. The analysis included the following potential prognostic factors: age, CA 125 value, stage according to classification of the International Federation of Gynecology and Obstetrics (FIGO), methods and radicality of operation, staging, tumor capsule rupture, histopathology, implants, ascites, and microinvasion. The analysis of relapses was also performed. Results Univariate analysis showed the negative impact of 2 factors on progression-free survival: FIGO II/III (implants) (P = 0.011) and ascites (P = 0.027). The multivariate analyses showed the detrimental effect of FIGO Ic (HR, 2.63; 95% confidence interval [CI], 1.12–6.17, P = 0.027), FIGO II or III (implants) (HR, 3.67; 95% CI, 1.56–8.61, P = 0.003), and incomplete staging (HR, 3.63; 95% CI, 1.09–12.07, P = 0.035), but not ascites (P > 0.1). Relapse occurred in 32 (10%) patients: in 22 patients as borderline and in 10 patients as invasive tumor. Seven (70%) patients with invasive relapse died of disease. All patients with borderline relapses were successfully managed by second surgery, which in 80% was again conservative. Conclusions Relapses in borderline ovarian tumor are uncommon, in 10% of patients. Invasive relapses are rare, only in 3% of patients, but often with fatal course irrespective of the treatment applied. The most important clinical risk factors of relapse are implants (FIGO II/III), FIGO Ic, and incomplete staging and this patients as well as patients with ascites should be closely followed. Relapses of borderline histology are easily detected and successfully managed by surgery.

Photodynamic therapy in the treatment of vulvar lichen sclerosus

BACKGROUND Vulvar lichen sclerosus is a chronic and incurable disease that causes various unpleasant symptoms and serious consequences. OBJECTIVE The purpose of the study was to assess the effectiveness of photodynamic therapy in the treatment of vulvar lichen sclerosus. METHODS Participants in the study included 102 female patients aged 19-85 suffer from vulvar lichen sclerosus. The patients underwent photodynamic therapy (PDT). In the course of PDT the 5% 5- aminolevulinic acid was used in gel form. The affected areas were irradiated with a halogenic lamp PhotoDyn 501 (590-760nm) during a 10-min radiation treatment. The treatment was repeated weekly for 10 weeks. RESULT PDT has brought about a good therapeutic effect (complete or partial clinical remission), with 87.25% improvement rate in patients suffering from lichen sclerosus. The greatest vulvoscopic response was observed in the reduction of subepithelial ecchymoses and teleangiectasia (78.95%), and the reduction of erosions and fissures (70.97%). A partial remission of lichenification with hyperkeratosis was observed in 51.61% of cases. The least response was observed in the atrophic lesions reduction (improvement in 37.36% of cases). CONCLUSION Our patients suffering from vulvar lichen sclerosus demonstrated positive responses to photodynamic therapy and the treatment was well tolerated. Photodynamic therapy used to treat lichen sclerosus yields excellent cosmetic results.

Comparison of efficiency of photodynamic diagnostics with topical use of the 3% and 15% aminolevulinic acid in the detection of vulvar lesions.

UNLABELLED The essence of the photodynamic diagnostic method is interaction between light and chemical compounds that form in reaction to light. In order to obtain fluorescence, tissue has to be exposed to energy in the form of light with the wavelength corresponding to the bandwidth of the photosensitizer absorption. The photodynamic method allows for the detection of even small lesions. This method facilitates the process of detecting vulvar cancer, especially in its early stages when it can develop on the foundation of overgrown epithelium. At that point the vulvoscopic image is difficult to interpret, in particular when multifocal growth occurs. OBJECTIVES The objective of the study was evaluating the efficiency of the photodynamic method PDD (photodynamic diagnosis) in the detection of vulvar lesions when two concentrations of the photosensitizer were used (3%- and 15%-aminolevulinic acid), as well as evaluating the efficiency of this method when compared to the efficiency of vulvoscopy, against the result of histological examination. METHODS Two concentrations of the 5-ALA cream (aminolevulinic acid) - 3% and 15% - were used in the PDD testing. The study group was divided into two subgroups A and B. In subgroup A the 15% eucerine-based cream was used. In subgroup B the 3% ALA gel with and addition of 2% DSMO was used. The photosensitizer was applied to the vulva 4-6h before the examination. In order to obtain fluorescence, energy in the form of light whose wavelength was approximately 405 nm, and whose source was a SLED diode, was transmitted to vulvar tissue. The positive result of the exam was obtaining tissue fluorescence. All patients underwent vulvoscopy and a histological examination of tissue samples was performed in all cases. The efficiency of the photodynamic testing in subgroups A and B was compared with the efficiency of vulvoscopy, against the result of histological examination. Sensitivity, specificity, as well as positive and negative predictive values of the PDD examination and vulvoscopy in both subgroups, were evaluated. RESULTS When the 15% ALA was used in detecting vulvar lesions, the photodynamic diagnostics was characterized by sensitivity of 100%, specificity of 92%, positive predictive value of 80%, negative predictive value of 100%, and correlation with the histopathological examination of 93.9%. When the 3% ALA was used, we observed: sensitivity of 100%, specificity of 91.4%, positive predictive value of 78.5%, negative predictive value of 100%, and correlation with the histopathological examination of 93.4%. Differences in the two subgroups were not statistically significant. CONCLUSIONS High correlation was observed between the accuracy of the photodynamic method of examining vulvar lesions and the accuracy of the histological examination, especially in cases of precancerous lesions and vulvar cancer. The photodynamic examination, when the 3%-ALA/2%DSMO is used, is characterized by a greater sensitivity, comparable specificity, as well as, comparable positive and negative prognostic values, in comparison to the vulvoscopic examination. The photodynamic method, when used with other diagnostic methods, facilitates performing the needle aspiration biopsy and allows for a greater precision of histological diagnoses. The pathological fluorescence obtained during the PDD examination gives information about the spread and multifocality of vulvar lesions, which can facilitate making presurgical decisions concerning the extensiveness of surgery. The photodynamic method, when the 3% ALA/2% DSMO is applied topically, is of comparable efficiency as the 15% ALA, in the detection of vulvar lesions. High safety of the photodynamic method was shown, both in terms of the topical application of the aminolevulinic acid and the subsequent use of light.

Zalecenia postępowania diagnostyczno-terapeutycznego u chorych na mięsaki macicy

1 Klinika Nowotworów Tkanek Miękkich, Kości i Czerniaków, Centrum Onkologii – Instytut im. Marii Skłodowskiej-Curie w Warszawie. Kierownik: prof. dr hab. n. med. Piotr Rutkowski 2 Klinika Ginekologii Onkologicznej, Centrum Onkologii – Instytut im. Marii Skłodowskiej-Curie w Warszawie. Kierownik: prof. dr hab. n. med. Beata Śpiewankiewicz Correspondence to: Klinika Nowotworów Tkanek Miękkich, Kości i Czerniaków, Centrum Onkologii – Instytut im. Marii Skłodowskiej-Curie, ul. Roentgena 5, 02-781 Warszawa, tel.: 22 643 93 75, e-mail: rutkowskip@coi.waw.pl Source of financing: Department own sources

New directions in cervical cancer prophylaxis worldwide and in Poland – Case study of the Polish rural female population

INTRODUCTION Cervical cancer is one of the most frequent malignant neoplasms in females. Such neoplasms can be almost completely eliminated by means of adequate primary and secondary prophylaxis. The most developed countries focus their attention on the improvement of prophylaxis systems, test quality, and efficacy improvement, as well as on the expansion of the primary prophylaxis. In Poland, the discussions focus on the improvement of the malfunctioning population programme. OBJECTIVE Drawing on recent research findings, the article presents current Polish and global recommendations with regard to screening tests for cervical cancer. The results of the Population Programme of Prophylaxis and Early Detection of Cervical Cancer are discussed in the context of current trends of healthy behaviour among women inhabiting rural areas. DESCRIPTION OF THE STATE OF KNOWLEDGE In the future, it will be relevant to increase the number of human papillary virus (HPV) tests as part of the prophylaxis programme, especially among the high risk patient group. In particular, there is a necessity to increase the number of vaccinations among young women, especially before the beginning of their sexual activity, as well as to establish new strategies of secondary prophylaxis in this group. At present, women who had been vaccinated should undergo routine screening. In Poland, the report based on SIMP registry (IT System of Prophylaxis Monitoring), shows that only 27% of the 3.3 million of invited women participated in the cytology tests. The data analysis shows that women living in rural areas more often respond and participate in the tests, compared to women living in the cities (39.3% vs. 16.8%).

Borderline ovarian tumors – diagnosis, treatment and follow-up

Tumors of borderline malignancy account for approximately 20% of all ovarian tumors. Their diagnostic criteria mainly include: the absence of...

Clear cell carcinoma of the ovary

Ovarian clear cell carcinoma belongs to rather rare ovarian neoplasms and is believed to be a separate disease with a...

Zasady stosowania dootrzewnowej chemioterapii w hipertermii (HIPEC) w leczeniu nowotworów złośliwych powierzchni otrzewnej w połączeniu z zabiegami cytoredukcyjnymi: zalecenia krajowe

The management of peritoneal surface malignancy is a significant clinical problem. The hyperthermic intraperitoneal chemotherapy (HIPEC) combined with cytoreductive surgery seems to be the most promising method, leading to better local control or improved overall survival in selected patients with a peritoneal neoplasm. In this paper the authors present a consensus for the optimal indications and technical guidelines for performing HIPEC in Poland.

Leczenie chirurgiczne zaawansowanego raka szyjki macicy a wytrzewienie – przeglad literatury

1 Department of Gynecology and Obstetrics, Essen, Germany. Kierownik: prof. med. Rainer Kimmig 2 Oddział Kliniczny Ginekologii Onkologicznej, Centrum Onkologii im. prof. Franciszka Łukaszczyka w Bydgoszczy. Kierownik Oddziału: prof. dr hab. n. med. Łukasz Wicherek 3 Klinika Chirurgii Onkologicznej i Urologii, Centrum Onkologii – Instytut im. Marii Skłodowskiej-Curie, Oddział w Krakowie. Kierownik Kliniki: prof. dr hab. n. med. Jerzy Mituś 4 Oddział Kliniczny Urologii Onkologicznej, Centrum Onkologii im. prof. Franciszka Łukaszczyka w Bydgoszczy. Kierownik Oddziału: dr n. med. Jerzy Siekiera 5 Zakład Mikrobiologii, Centrum Onkologii im. prof. Franciszka Łukaszczyka w Bydgoszczy. Kierownik Zakładu: dr n. med. Maria Szymankiewicz 6 Klinika Ginekologii Onkologicznej, Centrum Onkologii – Instytut im. Marii Skłodowskiej-Curie w Warszawie. Kierownik Kliniki: prof. dr hab. n. med. Beata Śpiewankiewicz 7 Klinika Ginekologii Onkologicznej, Centrum Onkologii – Instytut im. Marii Skłodowskiej-Curie, Oddział w Krakowie. Kierownik Kliniki: prof. dr hab. n. med. Krzysztof Urbański 8 Katedra i Klinika Ginekologii Onkologicznej i Pielęgniarstwa Ginekologicznego, Collegium Medicum UMK w Bydgoszczy. Kierownik Katedry i Kliniki: prof. dr hab. n. med. Łukasz Wicherek Adres do korespondencji: Prof. dr hab. n. med. Łukasz Wicherek, Oddział Kliniczny Ginekologii i Onkologii, Centrum Onkologii im. prof. Franciszka Łukaszczyka, ul. Romanowskiej 2, 85-796 Bydgoszcz, tel.: +48 52 374 33 99, +48 52 374 38 74, e-mail: mowicher@cyf-kr.edu.pl Podziękowanie Chcielibyśmy podziękować Dr. Zbigniewowi Pawłowiczowi i Prof. Jerzemu Stelmachowowi za okazaną pomoc, słowa wsparcia i zdolność przewidywania kierunków rozwoju medycyny. Zdjęcia przedstawione w manuskrypcie zostały wykonane podczas zabiegów wytrzewienia przeprowadzanych na Oddziale Klinicznym Ginekologii Onkologicznej, Centrum Onkologii w Bydgoszczy – za pomoc w ich wykonaniu dziękujemy Dr. Wojciechowi Polonceuszowi i Dr. Naserowi Alahmad Alali.

Practical considerations for intraoperative anesthesia in patients undergoing surgery in combination with hyperthermic intraperitoneal perfusion chemotherapy – a series of 60 cases

Uwagi praktyczne do śródoperacyjnej anestezji u pacjentów operowanych z zastosowaniem dootrzewnowej perfuzyjnej chemioterapii w warunkach hipertermii – seria 60 przypadków Practical considerations for intraoperative anesthesia in patients undergoing surgery in combination with hyperthermic intraperitoneal perfusion chemotherapy – a series of 60 cases Практические замечания по интраоперационной анестезии у пациентов оперированных с применением внутрибрюшинной перфузионной химиотерапии в условиях гипертермии – серия 60 случаев